Fentanyl intranasal spray - Kyowa Kirin International

Drug Profile

Fentanyl intranasal spray - Kyowa Kirin International

Alternative Names: Fentanyl; Fentanyl pectin; Fentanyl pectin nasal spray; FPNS; Lazanda; Nasalfent; PecFent

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator West Pharmaceutical Services
  • Developer AstraZeneca; Kyowa Kirin International; ProStrakan
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain
  • Phase I Anaesthesia

Most Recent Events

  • 26 May 2017 Phase-I development in Anaesthesia (Adjuvant therapy) is ongoing in USA (Intranasal, Spray)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anaesthesia(Adjuvant therapy) in USA (Intranasal, Spray)
  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top